<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>17 Central nervous system</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part22.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part24.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark23" class="s95" name="bookmark65">Chapter 17</a><a name="bookmark66">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 55pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_240.png"/></span></p><p style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark23" class="h2">Central nervous </a><h2 href="#bookmark23">system</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 53pt;text-indent: 0pt;line-height: 109%;text-align: left;">sara C. erridge, Gerard thompson, and David summers</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 12pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The purpose of imaging is to try to determine the nature, anatomical extent, and histo- logical type of an intracranial lesion (solitary or multiple; intra-parenchymal or extra- axial; benign or aggressive). The demonstration of the relationship between the lesion and the adjacent neuroanatomy allows more precise surgical planning and accurate targeting of radiotherapy treatment volumes. Imaging is also used to assess treat- ment response. Multidetector computed tomography (CT) and magnetic resonance imaging (MRI) permit detailed, non-invasive, structural, and morphological analysis of masses within the brain and spine. More recent developments in imaging such as MR spectroscopy, CT and MR perfusion, and MR diffusion imaging are providing further insights into tumour subtype, behaviour, and spread. At present none of the available imaging tools can predict the histological tumour type with sufficient cer- tainty, and pathological confirmation is obtained whenever practicable. Conversely, a small biopsy of a heterogeneous lesion may yield histological appearances compatible with low-grade tumour, when the imaging suggests a more aggressive neoplasm. Best practice requires the correlation of imaging and pathological findings, usually in the context of a multidisciplinary meeting.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">The choice of imaging modality in the assessment of a probable tumour depends</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">greatly on the issues which imaging is being asked to resolve. Both CT and MRI have strengths and weaknesses. MRI provides the best soft tissue contrast, displaying excel- lent definition of intracerebral structures, and shows anatomic detail and subtle con- trast enhancement not visible on CT. The panoply of modern MR techniques such as perfusion and diffusion imaging, spectroscopy, and functional studies may provide useful additional information beyond the macroscopic structure of an abnormality. These sequences are more complex and time consuming and are usually undertaken at tertiary centres. They may also require greater patient cooperation, so standard struc- tural MRI is the preferred modality for tumour imaging under most circumstances.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">CT is often the first examination performed, as multidetector CT is now fast, readily accessible, and allows multi-planar image reconstruction akin to MR, although the tissue contrast and the distinction between normal brain and tumour remains in- ferior. CT may be all that is required, for example in planning the resection of a skull vault meningioma, or acute assessment for hydrocephalus or bleed. CT has additional</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">advantages in the skull base where the quality of bone imaging is considerably better than MRI. CT can demonstrate lesion calcification that may not be readily visible on MRI. The two modalities are often complementary, for example in the assessment of a skull base tumour where high-resolution CT provides bone detail and MRI shows the extent of soft tissue involvement, or for detection of macroscopic calcification.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.2 <span class="h4">Advanced imaging techniques</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Over the last decade there has been extensive investigation of the role of advanced MRI and nuclear medicine techniques to improve the accuracy of initial radiological diagnosis, to identify the extent of tumour spread, guide biopsies, and to assess the post-treatment tumour status.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.2.1 <span class="s29">Magnetic resonance imaging techniques</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">MR spectroscopy examines the presence of specific metabolites in tissues, and in brain tumours has primarily been used to examine the levels of N-acetylasparate (NAA), creatine, choline, and lactate. The ratio of these compounds, for example NAA to cho- line, may help differentiate normal brain from tumour infiltration. The presence of the amino acid alanine has also been identified as a marker of meningioma. However, at present the low spatial resolution (6–10 mm) limits the use in target definition.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Diffusion weighted imaging (DWI) measures the ability of water to move primarily in the extracellular space, which in broad terms may become restricted in higher grade and cellular tumours, although the biological specificity remains uncertain. As with enhancement, it is non-specific, and diffusion restriction can be seen in infarct and postoperative tissue handling. As with other MRI techniques, interpretation can be- come challenging once blood products are present. Diffusion tensor imaging (DTI) examines the microarchitecture of tumours and white matter tracts, and these may be disrupted by tumour before macroscopic lesions are visible on standard MR sequences Figure 17.1a–c. This may be useful in the planning of radiotherapy, but whilst DWI is now part of standard brain tumour imaging protocols, DTI still requires additional time and expert image processing to perform well, is subject to technique and pro- cessing variability, and its availability is limited in many current clinical settings.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">		</p><p style="text-indent: 0pt;text-align: left;"><span><img width="127" height="153" alt="image" src="Image_241.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="119" height="153" alt="image" src="Image_242.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="179" height="153" alt="image" src="Image_243.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.1. <span class="s52">(a) Dti t2 map. (b) Dti structural map. (c) Dti fibre track.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Perfusion/permeability MR imaging attempts to measure the degree of angiogenesis and capillary permeability. There are a number of techniques in use. The role of perfu- sion imaging has yet to be fully established although it may be helpful in determining grade of astrocytic (but not oligodendroglial) lesions. Perfusion MRI may help differ- entiate post-treatment changes from tumour progression in conjunction with radio- logical interpretation (see below).</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.2.2 <span class="s29">Computed tomography techniques</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">CT perfusion is a more robust technique than MR, with a linear relationship between contrast density and cerebral blood flow and volume parameters, but like MR perfu- sion requires significant post-processing time. It also uses an ionizing radiation dose significantly higher than standard CT head imaging and is therefore less suited for follow-up imaging; newer systems with whole head coverage and reductions in ion- izing radiation dose may yet bring CT perfusion into more widespread clinical use.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.2.3 <span class="s29">Nuclear medicine techniques</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Single photon emission tomography (SPECT) and positron emission tomography (PET) scanning examine physiological parameters rather than structure. Although relatively low-resolution structural detail is captured they have been extensively in- vestigated in brain tumours. SPECT scanning uses a number of different radioisotope tracers, for example <span class="s22">99m</span>Tc-HMPAO (hexamethylpropylene amine oxime) to examine brain blood flow or <span class="s22">201</span>thallium chloride to identify areas of increased metabolism. However, the spatial resolution is inferior to CT-PET which has largely superseded SPECT as metabolic imaging of choice for research into brain lesions.</p><p class="s65" style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: justify;">18<span class="s44">Flourodeoxyglucose (FDG) PET scanning can be used in the evaluation of brain</span></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">tumours with the degree of uptake correlating with tumour grade and survival, but the high level of glucose metabolism in normal grey matter makes differentiation from tumour difficult. Other tracers, which identify increased amino acid uptake or increased protein or DNA synthesis, have also been developed. Amino acid PET in neuro-oncology has recently been appraised by the RANO initiative. The most com- monly used tracer in brain imaging is <span class="s22">11</span>C-methionine (MET), but the very short half- life of <span class="s22">11</span>carbon makes this tracer difficult to use. So other tracers using <span class="s22">18</span>fluoride have been developed, principally <span class="s22">18</span>fluorothymidine (FLT), which measures cell prolifer- ation rates, and <span class="s22">18</span>fluroethyl-L-tyrosine (FET) that assesses amino acid uptake. FLT is robust at grading tumours and predicting prognosis and FET may also prove useful in differentiating normal brain from tumour.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Although these techniques appear promising, whether or not these will prove useful and cost effective in routine practice requires prospective, ideally randomized, studies with health economic assessment.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.3 <span class="h4">How to review imaging of the CNS</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Having excluded a finding requiring immediate action, such as acute hydrocephalus or significant haemorrhage, the most important consideration, whether reviewing CT or MR, is to decide on the anatomical location of the lesion. In particular, is it</p><p class="s12" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">intra-parenchymal <span class="p">(within the substance of the brain) or </span>extra-axial <span class="p">(outside the brain itself, and arising from vault, dura, or other meninges). The differential diagnoses are distinct between these two groups, and making this distinction allows the possible causes to be narrowed considerably.</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.3.1 <span class="s29">Intraparenchymal</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A solitary intra-axial lesion may be either a primary tumour of the CNS, most com- monly a glioma, or a metastasis. The relative likelihood depends upon the patient’s age and the lesion site; for example a solitary posterior fossa lesion in a middle-aged adult is most likely to be a solitary metastasis (and 50% of brain metastases are solitary).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Intra-axial lesions expand or outwardly displace the cortical grey matter, narrowing the subarachnoid and extra-axial cerebrospinal fluid (CSF). The outer margins of the lesion may be distinct and sharp (as in a metastasis or gliosarcoma) or ill-defined and irregular (as in glioblastoma multiforme). As a gross generalization, more fast- growing lesions enhance more avidly, and the absence of central enhancement raises the possibility of necrosis or tumour cyst, although it should be noted that contrast enhancement is an epiphenomenon of blood-brain barrier disruption and vascularity as discussed below. Intra-axial tumours provoke varying degrees of surrounding white matter change. This is demonstrated as high signal on T2-weighted sequences and FLAIR imaging. It may be due to vasogenic tumour oedema, tumour infiltration, or both. This is a particular problem for intra-axial primary tumours, where definition of the tumour margin is important for planning radiotherapy and an area of active dis- cussion and research.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.3.2 <span class="s29">Extra-axial</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Extra-axial masses are commonly benign, with meningiomas forming the largest group. Typical features include a sharp cleft of CSF between the lesion and the cortical surface, and a broad base on the dura or the skull. Inward displacement of cortical ves- sels is also a useful imaging sign. Other lesions include bone and dural metastases, and tumours of nerve sheathes such as vestibular schwannomas. This latter group is usually easily identifiable by their anatomical location. The presence of a tail of enhancement along the dura is a feature of extra-axial lesions, but is not specific to meningioma.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.3.3 <span class="s29">Other features</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In addition to location, other factors, such as the degree of enhancement following the injection of contrast media, can help differentiate between types of tumour. Tumour enhancement, whether on MRI or CT, reflects either disruption of the normal blood- brain barrier, significantly increased vascularity of a lesion, or a combination of both. Assessment of contrast enhancement characteristics is an essential part of the diag- nostic study so only patients with a known allergic reaction to contrast media or significantly impaired renal function should not receive contrast. The enhancement characteristics do not necessarily directly correlate with tumour grade. For example, meningiomas usually enhance uniformly and avidly, whilst some moderately aggres- sive gliomas may demonstrate only minor enhancement.</p><p class="s96" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.4 <span class="h4">Role of imaging in treatment planning</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Imaging now plays a central role in the planning of surgery and radiotherapy for all CNS lesions.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Prior to surgery most patients will have a volumetric MRI scan performed, which can be used in conjunction with a neuro-navigation system to help guide surgery. This enables the surgeon to perform framed or frameless stereotactic craniotomies and bi- opsies, guiding them to a specific area on a scan which is co-registered with the patient in theatre. Surgical instruments are tracked in three dimensions by this system and matched to the imaging volume. These systems are used during a resection in com- bination with anatomical knowledge and preoperative functional imaging planning to establish how much tumour tissue can be removed safely. Some larger neurosur- gical centres have intra-operative MRI scanners, usually in a room adjacent to the neurosurgical theatre, which perform a scan during the procedure to assess whether the planned extent of resection has been achieved and to guide any further surgery, allowing account to be taken of brain shift during the procedure.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">When the tumour is close to an eloquent area of brain, a preoperative functional MRI (fMRI) may be performed to assess the potential impact of a resection. This can be used in conjunction with neuro-navigation and an awake craniotomy. For example, if the le- sion is close to eloquent speech/language cortex the patient can be instructed to perform naming tasks during the operation to maximize preservation of eloquent brain areas.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">When planning radiotherapy for CNS lesions, though the planning CT scan can provide information on tumour location, the inferior tissue contrast makes the images less suitable for target delineation than MRI. Therefore, when defining radiotherapy target volumes for CNS tumours fused CT/MRI images should be used. The accuracy of alignment varies so this should always be inspected carefully, and repeated or ad- justed if necessary.</p><p class="s96" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.5 <span class="h4">Intra-parenchymal tumours</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Intra-parenchymal tumours arise from neuroglial progenitor cells and demonstrate features relating to two distinct lineages of glial cells: oligodendrocytes, which form and maintain the myelin sheath around axons, and astrocytes, which undertake a number of functions for maintaining CNS function, for example metabolic support for neurons, interacting with vasculature as a component of the blood-brain barrier, formation of synapses, and interaction with the immune system. They can also exhibit behaviours present during neurodevelopmental processes such as migration, in add- ition to uncontrolled proliferation. These properties are postulated to contribute to the treatment resistance and heterogeneity demonstrated by gliomas. Ependymomas are also considered in this category.</p><p class="s96" style="padding-top: 11pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.6 <span class="h4">Astrocytomas</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.6.1 <span class="s29">Glioblastoma (grade IV)</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These fast-growing tumours account for around half of all malignant tumours and occur most frequently between the ages of 45 and 70 and are more common in</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">men. Glioblastomas (GBM) are rare in children, but if they do occur, they may be infra-tentorial.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">GBM with IDH mutations have transformed from a lower grade tumour, occur in younger people, and have a better prognosis than GBH with IDH wildtype. Glioblastomas are also classified by the presence or absence of methyl-guanine methyl transferase (MGMT) promoter methylation; so-called ‘methylated glioblastomas’ have a better prognosis and are more likely to respond to alkylating chemotherapy, such as temozolomide (TMZ). MGMT promoter methylation silences the MGMT enzyme, which is a key DNA repair mechanism for alkylation and therefore impedes the effect- iveness of TMZ.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Infiltrative growth is characteristic, with spread along white matter tracts, for example across the corpus callosum, the internal capsule, fornix, or anterior commissure. Multifocal lesions occasionally occur and have a worse prognosis. Spread via the CSF is relatively rare (slightly more common in ‘glioblastoma with PNET features’) and extraneural metastases are even rarer, but are occasionally observed in long-term survivors.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.1.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figures 17.2a and 17.2b.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Complex-looking tumour</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Cystic or necrotic centre, but with some enhancing structures within</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Irregular thick enhancing walls on T1-weighted MRI following gadolinium (Gd) chelate</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually moderate mass effect</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Moderate surrounding white matter high signal on T2-weighted/FLAIR</span></p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Predilection for white matter tracts, for example cross corpus callosum/ commissures</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Haemorrhage uncommon but can precipitate clinical deterioration</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Calcification rare</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.1.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy target delineation should be performed on a contrast enhanced CT scan (slice thickness 3 mm or less) performed in an immobilization mask. The pre- operative and postoperative MRI scans should be fused to the CT scan. The preopera- tive imaging can be helpful in locating all areas of disease, but when a resection has been performed the shift of structures can result in movement of the target, hence the need for a postoperative MRI also to be fused. However, sometimes postoperative scans can have enhancement due to surgical changes, so having both pre- and postoperative MRI scans fused can aid identification of all areas at risk. Immediate postoperative MRI is generally recommended within 48–72 hours. The most com- monly utilized sequences are gadolinium enhanced volumetric T1w and volumetric FLAIR. Volumetric sequences are acquired with reduced distortion and have more slices, enabling more accurate fusion. In general, isotropic voxels should be acquired to permit multiplanar reformatting. The T1w image with gadolinium demonstrates</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 26pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="196" alt="image" src="Image_244.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="196" alt="image" src="Image_245.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.2. <span class="s52">(a) t1-weighted gadolinium enhanced axial section. (b) t2-weighted axial section.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">any residual enhancing tumour and the resection cavity. A pre-contrast T1-weighted volume using the same sequence parameters is useful to distinguish genuine en- hancement from postoperative blood products. The FLAIR shows areas of infiltrative tumour, though will also include areas of oedema, particularly on the preoperative scan acquired prior to commencing steroids.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The gross target volume (GTV) should consist of the area of residual enhancing tumour or resection cavity defined on T1-weighted with gadolinium, adjusted to take into account any areas of new enhancement on the planning CT scan.<span class="s22">1</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The clinical target volume (CTV) should include areas of greatest likelihood of microscopic spread, created by adding a 2 cm margin to the GTV, edited to remove anatomical barriers to spread (e.g. tentorium cerebelli, the falx cerebri, or the contralat- eral ventricle). The recommendation of a 2 cm margin is based on a number of single- centre retrospective analyses of recurrence patterns which have shown that around 80% occur within this margin. This volume should then be inspected to consider areas of potential spread as glioma cells migrate along white matter tracts and in perineural and perivascular spaces. The FLAIR sequence can help identify these areas, as can en- largement of gyri when compared to contralateral side. The subventricular region has been identified as a site harbouring neural stem cells and some authors recommend including this region in the CTV. Studies are ongoing to see if MRI sequences such as DTI or physiological imaging such as PET will enable more individualized targets to be created.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.6.2 <span class="s29">Anaplastic astrocytoma (grade III non-codeleted glioma)</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In the 2016 WHO reclassification of brain tumours, grade III lesions have been de- fined by the presence or absence of loss of the short arm of the first chromosome (1p) and long arm of chromosome 19 (19q) as either co-deleted (anaplastic oligo- dendroglioma) or non-codeleted (anaplastic astrocytoma).<span class="s22">2 </span>Anaplastic astrocytoma represents around 20% of astrocytomas, and occurs at a slightly younger age than glio- blastomas. There may be evidence of progression from a grade II diffuse astrocytoma</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">when there is usually IDH mutation and ATRX mutation. They are diffuse lesions with marked cellular atypia and mitotic activity but without frank or geographic necrosis. They have a similar growth pattern to glioblastoma</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.2.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figure 17.3.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Infiltrative mass, predominantly along white matter tracts</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Uniformly high signal on T2-weighted sequences</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Often of considerable size with local mass effect</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Typically, does not enhance, but small focal areas of enhancement may occur</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.2.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Similar target volumes to GBM are used with most neuro-oncologists recommending a 1.5–2 cm margin to be added to the contrast enhancing region demonstrated on T1-weighted postoperative MRI but as they often derive from lower grade glioma and are less likely to have oedema, any changes on the FLAIR sequence are likely to repre- sent tumour infiltration so should be included in the CTV.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.3 <span class="s29">Diffuse astrocytoma (grade II non-codeleted glioma)</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These lesions represent around 15% of all astrocytomas and are diagnosed most fre- quently in early adulthood. They can occur anywhere in the brain, with the temporal</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="305" height="315" alt="image" src="Image_246.gif"/></span></p><p class="s24" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.3 <span class="s52">anaplastic astrocytoma t1-weighted gadolinium enhanced axial section.</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">and frontal lobes most commonly affected. Histologically there is increased cellu- larity and nuclear atypia but mitotic activity is low. The majority have IDH mutation present and the absence of this, after full sequencing, raises the concerns that the lesion may behave more like a higher-grade glioma (pre-GBM). Diffuse astrocytoma by definition do not have 1p/19q co-deletion.</p><p style="padding-left: 19pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Certain features suggest a more ‘aggressive’ clinical course:</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">1) Size &gt;5 cm</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">2) Crossing mid-line</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">3) Age &gt;40 years</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">4) Localizing clinical signs</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">5) Shorter history of symptoms</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.6.3.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.4.</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bland homogeneous lesions, usually in frontal or temporal lobes</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually uniform T2-weighted high signal</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Infiltrate along white matter tracts</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Contrast enhancement absent or minimal</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Often less mass effect than expected for lesion size</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May be indistinguishable from anaplastic astrocytoma</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="305" height="301" alt="image" src="Image_247.gif"/></span></p><p class="s24" style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.4 <span class="s52">Diffuse astrocytoma t2-weighted axial section.</span></p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.3.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">When defining the target for a low-grade glioma it is particularly important to use fused MRI images. The FLAIR sequence can be particularly useful to generate the GTV as the areas of high signal are likely to represent tumour. To create the CTV, a margin of 1.0–1.5 cm is added. As the prognosis of this group of patients, particularly when IDH mutation is present, is good, then the CTV should be edited to remove any regions where tumour spread is unlikely.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.4 <span class="s29">Pilocytic astrocytoma (grade I)</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These well-circumscribed, slow-growing tumours usually occur in children and young adults, but can occur at any age. They can occur anywhere throughout the neuraxis but frequently occur in the cerebellar hemispheres (60%) (‘cerebellar astrocytoma’), optic pathway (30%) (‘optic pathway glioma’ OPG, particularly seen in patients with neurofibromatosis type 1 (NF1)), third ventricle, and hypothalamus (also associated with NF1). They have heterogeneous histology, including areas of compact bipolar cells with long processes and other regions with microcysts.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.6.4.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figure 17.5.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Avid enhancement of mural nodule</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Rounded cyst or cysts</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="304" alt="image" src="Image_248.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.5 <span class="s52">pilocytic astrocytoma, t1-weighted gadolinium enhanced axial section.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Variable size of cyst(s), usually without enhancement in cyst wall</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Sharply defined margins with normal brain</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.6.4.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most pilocytic astrocytomas can be successfully treated with resection, requiring no additional therapy. However, occasionally a lesion grows or recurs locally or even seeds along the neural axis. When local radiotherapy is required the GTV is the enhancing tumour nodule and cyst with a small margin 0.3–0.5 cm used to create the CTV.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.7 <span class="h4">Oligodendrogliomas (codeleted glioma)</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.7.1 <span class="s29">Oligodendrogliomas (grade II)</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In the revised WHO 2016 classification, oligodendrogliomas are defined by a codeletion of the short arm of chromosome 1 (1p) and long arm of chromosome 19 (19q), and IDH mutation. If these are not present then the lesion is classified as a non-codeleted glioma (astrocytoma). If the molecular characterization is not available then WHO 2016 allows for the traditional histological phenotype to be employed carrying the suffix NOS for not otherwise specified but, whenever available, the molecular marker supersedes the histological appearances.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: right;">Oligodendroglioma are slow-growing infiltrative gliomas usually occurring supra- tentorially. They are typically located peripherally in the frontal lobe. One of the path- ognomonic features is the presence of dense foci of macrocalcification. Historically they were often diagnosed in the early to mid-40s, but the routine use of imaging in the investigation of seizures means many are now diagnosed at a younger age. The classic histological features are of tumour cells with clear cytoplasm (‘fried egg cells’), a branching network of capillaries (chicken wire appearance), and microcalcification. As with diffuse astrocytoma, the management of co-deleted grade II glioma has changed in recent years, with more undergoing surgical resection followed by imme- diate postoperative radiotherapy and adjuvant PCV chemotherapy, particularly if the</p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">postoperative characteristics meet the RTOG 9802 entry criteria.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.7.1.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.6.</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Peripheral location</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Most commonly frontal</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Nodular calcification in 80%+, best seen on CT</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Margins often relatively well-defined</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May contain cystic areas</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Variable enhancement, usually heterogeneous within tumour and can wax and wane</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Haemorrhage in 20%</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Skull vault may be scalloped</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 16pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="207" height="186" alt="image" src="Image_249.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="186" alt="image" src="Image_250.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 17.6 <span class="s52">(a) Ct scan showing calcification in grade 2 co-deleted glioma. (b) FlaiR image of grade 2 co-deleted glioma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.7.1.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">When defining the target for oligodendroglioma, the FLAIR sequence can be particu- larly useful to identify all the infiltrating tumour and then a margin of 1.0–1.5 cm is added to create the CTV. In light of the likelihood of prolonged survival there should be every effort to minimize the volume of normal brain, editing out areas where tu- mour spread is unlikely.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.7.2 <span class="s29">Anaplastic oligodendroglioma (grade III)</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These lesions usually occur on the background of a grade II codeleted lesion and are diagnosed at a slightly older age. The features of a grade II oligodendroglioma are pre- sent, along with marked nuclear atypia, high mitotic activity, and sometimes the pres- ence of vascular proliferation and necrosis. Standard management of these tumours is maximal safe debulking followed by radiotherapy and then adjuvant (or neo-adjuvant) PCV chemotherapy.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.7.2.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figures 17.7a and 17.7b.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Similar to grade II oligodendroglioma but more aggressive features include:</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Avid enhancement, or new areas of enhancement, which continue to enlarge</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Increasing mass effect</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Extensive cystic change</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.7.2.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">As these often occur in the background of a low-grade lesion the GTV consists of postoperative cavity and all enhancing disease on T1-weighted gadolinium enhanced MRI and all areas of high signal on the FLAIR. To create the CTV a margin of 1.5– 2 cm is added, but as these lesions can also have a good prognosis the volume should be carefully edited to remove areas where spread is unlikely.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 29pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="232" alt="image" src="Image_251.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="183" height="232" alt="image" src="Image_252.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 17.7 <span class="s52">(a) Ct image of anaplastic oligodendroglioma. (b) t2-weighted MR image of anaplastic oligodendroglioma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.8 <span class="h4">Mixed gliomas</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">With improved molecular profiling using 1p/19q and ATRX, true mosaic oligo- astrocytomas are very rare.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.8.1 <span class="s29">Gliomatosis cerebri</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Historically this term was used to define tumours involving three or more lobes but this entity was removed in the WHO 2016 reclassification. Instead the tumour is de- fined by its morphological and molecular features and the growth pattern only men- tioned as a description.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.8.2 <span class="s29">Gliomas of the spinal cord</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">See Figure 17.8.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: left;">These are relatively rare, principally diffuse astrocytoma and anaplastic astrocytoma, though glioblastomas do occasionally occur.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.8.2.1 <span class="s98">Follow-up imaging for glioma</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The interpretation of images acquired following surgery or radiotherapy can be challen- ging and result in a degree of uncertainty during follow-up. For patients in whom a gross total tumour resection was intended, an immediate postoperative MRI is useful for esti- mation of extent of resection. Postoperative MRI should be performed within 72 hours of surgery to minimize the enhancement due to surgical reaction and granulation tissue which generally becomes more prominent after this time. Imaging may, however, be con- founded by post-surgical haematoma and mass effect. Alternatively, imaging after several weeks may be performed when such postoperative changes have generally resolved.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="350" alt="image" src="Image_253.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.8 <span class="s52">t2-weighted sagittal image showing spinal cord astrocytoma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Following radiotherapy there are marked changes, particularly in the white matter, with high T2-weighted and FLAIR signal with facilitated diffusion which can take a number of months to resolve or may result in permanent microvascular-related changes. The appreciation of these changes is particularly important following con- current chemo-radiation as they can be falsely interpreted as tumour progression.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: right;">Radiation necrosis is unusual, but when it occurs there is often mass effect, irregular peripheral enhancement and necrosis, and it is difficult to distinguish from recurrent high-grade tumour on structural imaging alone. MR perfusion demonstrates reduced relative cerebral blood volume (rCBV) areas within radiation necrosis (as compared with generally increased relative blood volume in recurrent tumour)(Figure 17.9a and 17.9b), and MR spectroscopy shows an increase in lipid/lactate peak with decreases in all other metabolites in radiation necrosis, unlike recurrent tumour. Other modalities such as PET-CT with FDG can demonstrate the hypometabolism of radiation necrosis. The optimal follow-up schedule for high-grade glioma has not been established and depends on the patient’s fitness for treatment at progression. Some centres per- form imaging every 3–4 months in order to detect small recurrences amenable to re-resection, whereas other neuro-oncologists feel that the early detection of asymp-</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">tomatic recurrence is unlikely to be beneficial.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 20pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="253" alt="image" src="Image_254.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="206" height="253" alt="image" src="Image_255.jpg"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.9 <span class="s52">(a) t1-weighted gadolinium enhancing imaging showing radiation necrosis.</span></p><p class="s52" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">(b) MR perfusion showing rCBV within radiation necrosis.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For patients with low-grade lesions, especially where there are more treatment options, patients are usually followed with routine MRI scanning, initially every 3– 6 months to assess growth characteristics and then annually.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.9 <span class="h4">Ependymoma</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These tumours arise from the ependymal lining of the cerebral ventricles and from the central canal of the spinal cord.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Ependymomas account for around 3% of CNS lesions, and although they occur mainly in children and young adults they are seen at any age. They commonly de- velop in the posterior fossa, spinal cord, or lateral ventricles. They can spread along the neuraxis, so whole brain and spine imaging should be performed. They can be either grade I (myxopapillary), II, or III (anaplastic). Lesions in the brain, particularly supra- tentorial are associated with an inferior outcome, as is age over 40 years of age, grade III lesions, and subtotal excision.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.9.1 <span class="s29">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.10.</p><p style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;"><span class="s23">◆ </span>Typically arise from the <i>floor </i>of the fourth ventricle</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Conform to shape of ventricle</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Extend through foramina of Luschka and Magendie</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Enhancement variable, often mild and heterogeneous</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">‘Drop metastases’ into spine and CSF spaces are common</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="262" alt="image" src="Image_256.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.10 <span class="s52">t1-weighted gadolinium enhanced MRi showing fourth ventricular ependymoma.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.9.2 <span class="s29">Target definition</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Immediate postoperative radiotherapy is usually recommended for ependymoma, except for grade II lesions when a complete resection has been performed and sur- veillance can be adopted. Historically, because of the propensity for CSF seeding, craniospinal radiotherapy was recommended, especially for the anaplastic lesions. However, there is now a clear body of evidence that provided whole neuraxis imaging and CSF are clear then focal radiotherapy can be utilized.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The GTV is delineated on gadolinium enhanced T1-weighted MRI to include re- section cavity and any residual disease. The CTV consists of a margin of 1–2.5 cm depending on grade and location.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.10 <span class="h4">Spinal cord myxopapillary ependymoma (grade I)</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These low-grade lesions principally occur in the conus and cauda equina, growing very slowly over years. CSF spread has been documented but is uncommon.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.10.1 <span class="s29">Imaging features</span></p><p class="s23" style="padding-top: 6pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Well demarcated mass centred on conus or filum terminale/cauda equina (key feature)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Haemorrhage common</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Enhancement typical</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Bony canal may be expanded</span></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.10.2 <span class="s29">Radiotherapy target definition</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">As complete surgical resection is difficult, often a combination of subtotal resection and radiotherapy is used and has very good long-term control rates.<span class="s22">3 </span>The target should encompass the whole spinal canal extending from 2cm to 3 cm above the lesion to the thecal sac.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.10.3 <span class="s29">Follow-up of ependymal lesions</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">These patients usually undergo MRI imaging every 3–6 months.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.11 <span class="h4">Embryonal tumours</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This group of undifferentiated round-cell tumours occur principally in children and young adults. Medulloblastomas, which occur in the cerebellar region, are the most common type of lesion.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.11.1 <span class="s29">Medulloblastoma</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These are typically midline tumours arising from the roof of fourth ventricle posteriorly (unlike fourth ventricular ependymoma) growing to occupy the ventricle. In older age groups the lesion may arise laterally in the cerebellar hemispheres. Medulloblastomas are now grouped into four subtypes depending on the presence or absence of sonic hedgehog (SHH), WNT, and p53 mutations.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.11.1.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.11.</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually solid, rounded, slightly heterogeneous mass</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Small intralesional cysts common, large tumour cyst rare</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Well-defined margins, little oedema</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Do not grow through foramina of fourth ventricle (unlike ependymoma)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Heterogeneous enhancement in more than 80% cases</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Early leptomeningeal spread so post-contrast imaging of the whole of the brain and spine is required for complete staging</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Diffusion restriction (lower ADC values than normal hindbrain)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Lateral epicentre in cerebellum more likely to be SHH mutated</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Cerebellar peduncle epicentre more likely to be WNT mutated</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.11.1.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Because of their tendency to disseminate throughout the neuraxis, patients with medulloblastoma should be treated with craniospinal irradiation encompassing the whole of the meninges. Particular attention should be paid to the cribriform plate, the optic nerve reflection, the temporal lobe reflection, and any post-surgical menin- gocele. The inferior limit of the thecal sac (sacral cul-de-sac) should be defined indi- vidually using the MRI imaging of the spine. The boost usually consists of the whole</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="353" alt="image" src="Image_257.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.11 <span class="s52">t2-weighted axial MRi showing medulloblastoma in the fourth ventricular region.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">of the posterior fossa, defined using fused MRI scan with the inferior border at C2/3 junction.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.11.1.3 <span class="s98">Follow-up of patients with embryonal tumours</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most patients are followed up by routine post-contrast MRI of the CNS axis every 3–6 months for five years and then annually.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.12 <span class="h4">Primary CNS lymphoma</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">PCNSL are usually B cell lymphomas, though T cell lesions are well recognized. They occur most commonly in the supratentorial white matter, usually in periventricular re- gions or in the deep grey matter nuclei. They may cross the corpus callosum, extending along ventricular ependyma and may be multifocal. Though normally occurring in older patients, PCNSL also occurs in patients with immunosuppression either from HIV-AIDS or post-transplantation, when they can appear more heterogeneous.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.12.1 <span class="s29">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">See Figures 17.12a and 17.12b.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually enhances avidly and uniformly</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 29pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="183" height="207" alt="image" src="Image_258.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="207" alt="image" src="Image_259.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.12 <span class="s52">pCnsl (a) t1-weighted gadolinium enhancing axial MRi. (b) aDC imaging.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s23" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Necrosis or cyst formation rare unless immune-compromised</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">High density on pre-contrast CT, and restricted diffusion on DWI MR—reflects tumour cellularity and packing</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Minor oedema for lesion size</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Calcification rare pre-treatment</span></p><p class="s23" style="padding-top: 2pt;padding-left: 23pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">In immunocompromised patients the appearances are very different—often appearing as ring enhancing lesions</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.12.2 <span class="s29">Radiotherapy target definition</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The role of post-chemotherapy radiotherapy, particularly in older patients, is contro- versial because of concerns about late neurocognitive toxicity. However, when radio- therapy is delivered, the whole of the cranial meninges encompassing the optic nerve reflection, base of temporal lobes, and taking the inferior border to the C2/3 junction should be treated and any residual disease boosted with a margin of 1–2 cm.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.12.3 <span class="s29">Follow-up imaging following treatment for PCNSL</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This is highly dependent on the clinical condition of the patient and if radiotherapy has been used. If it has been decided to defer radiotherapy then routine imaging every 3–6 months is usually performed to detect any asymptomatic recurrence at an early stage when radiotherapy maybe more effective.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.13 <span class="h4">Pineal lesions</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Lesions in this region can either arise from the pineal parenchyma itself or represent metastases.</p><p style="padding-top: 2pt;padding-left: 23pt;text-indent: -12pt;line-height: 94%;text-align: left;">1) Pineoblastoma—embryonal lesions which can disseminate throughout the neuraxis.</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">2) Pineocytoma—relatively benign, slow-growing lesions.</p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">3) Pineal tumour of intermediate differentiation.</p><p style="padding-top: 2pt;padding-left: 17pt;text-indent: -12pt;line-height: 94%;text-align: justify;">4) Germ cell lesions (germinoma (akin to seminoma of testes), teratoma, yolk sac tumours, embryonal carcinoma, or choriocarcinoma). The pineal gland is the com- monest site of intracranial germ cell tumours, though they can occur anywhere, most often in the midline.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">17.13.1 <span class="s29">Imaging features</span></p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.13.1.1 <span class="s98">Pineocytoma</span></p><p class="s23" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Well defined</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Generally, under 3 cm</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Homogeneous signal</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Avid homogeneous enhancement</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May be cystic and can resemble pineal cyst</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Obstructive hydrocephalus rare</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Pineal calcification pushed peripherally</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.13.1.2 <span class="s98">Pineoblastoma</span></p><p class="s23" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Aggressive, heterogeneous appearance</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Generally, over 4 cm reflecting growth rate</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Infiltration into nearby structures</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Enhancement often only moderate</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Multi-cystic/necrotic change</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Obstructive hydrocephalus common</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Pineal calcification pushed peripherally</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.13.1.3 <span class="s98">Germ cell tumours</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figure 17.13.</p><p class="s23" style="padding-top: 2pt;padding-left: 17pt;text-indent: -11pt;line-height: 94%;text-align: left;">◆ <span class="p">Germinoma—homogeneous and often low T2-weighted signal with avid homoge- neous enhancement</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Calcification often remains central within tumour mass</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">‘Mature’ teratoma may show differentiation into fat and dense calcification</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.13.1.4 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Classically pineoblastoma and germ cell lesions disseminate throughout the CSF. They have been classically treated with craniospinal irradiation with a boost to the local tumour with a 1–2 cm margin. However, clinical trials have been conducted to estab- lish whether or not equivalent results can be achieved with chemotherapy followed by more focal radiotherapy, but the final results are awaited.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="338" alt="image" src="Image_260.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.13 <span class="s52">pineal germinoma t1-weighted gadolinium enhanced sagittal MRi.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.13.1.5 <span class="s98">Follow-up imaging for patients with pineal lesions</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Most patients undergo craniospinal axis imaging every 3–6 months to detect recur- rences which could be treated with chemotherapy.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.14 <span class="h4">Brain metastases</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Secondary spread to the brain is common, with some autopsy series finding up to a quarter of cancer patients have intracranial spread. Classically, the commonest pri- mary tumours to spread to the brain are lung (11% at initial diagnosis), renal, mel- anoma, and breast cancers. With better systemic local control, the brain is becoming a more frequent site of late relapse for patients.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For many years, whole brain radiotherapy was the mainstay of treatment for brain metastases, but concerns about neurotoxicity and efficacy have led to a reduction in its use. Focal treatment using stereotactic radiosurgery (SRS) has been shown to improve overall survival for patients with one metastasis and stabilize neurological function in those with up to four metastases. The use of SRS when more than four metastases are present is controversial and trials are ongoing for this group, comparing SRS with whole brain radiotherapy.</p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.14.1 <span class="s29">Imaging appearance</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">See Figure 17.14.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Well defined lesions, sharp interface with brain parenchyma</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually located peripherally at grey-white junction</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Posterior fossa lesions common</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May be cystic, solid, or mixed</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Often provoke marked adjacent white matter oedema for lesion size</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Look carefully for subtle, additional lesions which may inform management</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.14.2 <span class="s29">Radiotherapy target definition</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">For SRS, the GTV is delineated on a fused volumetric T1-weighted gadolinium en- hanced MRI encompassing all areas of enhancement. The addition of a margin to create a CTV is debated; historically 1–3 mm were added but one study has suggested that this may not be required.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="331" alt="image" src="Image_261.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.14 <span class="s52">Brain metastasis on t1-weighted gadolinium enhanced MRi.</span></p><p class="s96" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.15 <span class="h4">Extra-axial tumours</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.15.1 <span class="s29">Meningioma</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These are the commonest extra-axial lesions, accounting for around 38% of all CNS tumours. They present most frequently in the fifth and sixth decades of life and are the only CNS lesion to occur more frequently in women. Most intracerebral meningiomas are associated with the falx cerebri or dura over the cerebral convexity, but they also occur around the orbit and base of skull. Spinal meningiomas are most common in the thoracic region.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The majority of meningiomas are WHO grade I lesions with a low mitotic rate, but around 20% are atypical (grade II) with increased cellularity and mitotic activity. Around 2% are malignant lesions (grade III) with fast growth rates. The presence of brain invasion is associated with reduced local control, so tumours with this are now classified as grade II or III.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.15.1.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.15.</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Well defined extra-axial mass</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Broad dural base</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">CSF cleft between lesion and brain</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Inward displacement of cortical vessels</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="352" alt="image" src="Image_262.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.15 <span class="s52">Meningioma on t1-weighted gadolinium enhanced MRi.</span></p><p class="s23" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Uniform avid enhancement</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Adjacent bony hyperostosis</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Radial vessel ‘spokes’ within, from a point towards the base</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Parenchymal vasogenic oedema/white matter gliosis</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">A ‘tail’ of enhancement may extend along the adjacent dura (non-specific)</span></p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.15.1.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The GTV should consist of the enhancing tumour on T1-weighted MRI. The inclusion of the thickened enhancing dural tails and hyperostotic bone remains controversial, but they are usually included.<span class="s22">4 </span>The margin for the CTV depends on the tumour grade, with grade I lesions treated with 0–3 mm margin, but grade II or III lesions a margin of 5–10 mm is added.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.15.1.3 <span class="s98">Follow-up imaging for meningioma</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">To detect recurrences when they are potentially amenable to salvage surgery most patients undergo MR imaging three months after surgery or six months after radio- therapy and then annually for three years for grade I lesions and five years for grade II lesions and then alternate years to ten years after treatment. Grade III lesions are usually imaged more frequently.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.16 <span class="h4">Tumours of the sellar region</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">There are three principal neoplastic lesions which occur at this location; pituitary ad- enomas, craniopharyngiomas, and meningiomas.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.16.1 <span class="s29">Pituitary adenomas</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These benign lesions present either with hormonal effects or local symptoms such as visual disturbance. They are defined as either microadenomas (&lt;1 cm) or macroadenomas (&gt;1 cm). and can be functioning or non-functioning, dependent on clinical presentation and pituitary function results.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.16.1.1 <span class="s98">Imaging features</span></p><p class="s91" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Pituitary microadenoma</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Intra-pituitary mass</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Enhance less rapidly than normal pituitary (i.e. hypointense on post-Gd imaging)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Distortion of superior border of gland</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May be difficult or impossible to see despite biochemical abnormality</span></p><p class="s91" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">Pituitary macroadenoma</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">See Figure 17.16.</p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Large sellar mass with suprasellar extension</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">‘Cottage loaf ’ or ‘snowman’ appearance</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Usually enhance avidly</span></p><p class="s23" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May contain cysts or haemorrhage</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="254" alt="image" src="Image_263.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.16 <span class="s52">pituitary macroadenoma on t1-weighted gadolinium enhanced MRi.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s23" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May invade cavernous sinuses, pituitary fossa floor</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Infundibular displacement away from epicentre of mass</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Suprasellar component may threaten chiasm</span></p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.16.1.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy is usually offered to patients with an enlarging postoperative residuum or in whom surgery has not cured a functional lesion. The treatment should be planned using T1w gadolinium enhanced MRI scan using preoperative and postoperative im- ages. The target for macroadenomas includes the whole of the pituitary fossa, paying particular attention to any areas of cavernous sinus invasion, and to the roof of the sphenoid sinus following trans-sphenoidal surgery.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For microadenomas it may be possible to target just the lesion but anatomical dis- tortion following surgery can make this challenging.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.16.2 <span class="s29">Craniopharyngiomas</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These occur mainly in children, but they may also diagnosed in adulthood. Patients present commonly with visual disturbance or hormonal problems (such as diabetes insipidus) but children may present with a non-specific cognitive change.</p><p class="s97" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.16.2.1 <span class="s98">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.17.</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Mixed cystic and solid mass centred on suprasellar cistern</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Enhancement of solid components and cyst walls</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Calcification occurs in 90%, best seen on CT</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">The pituitary may be visible separate from the mass</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="316" alt="image" src="Image_264.gif"/></span></p><p class="s24" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.17 <span class="s52">Craniopharyngioma on t1-weighted gadolinium enhanced MRi (coronal section).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.16.2.2 <span class="s98">Radiotherapy target definition</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy should be planned using a postoperative gadolinium enhanced T1w MRI. The GTV is any residual solid tumour and cyst. No margin is required for the CTV.</p><p class="s97" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.16.2.3 <span class="s98">Follow-up imaging</span></p><p style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Following radiotherapy, the cyst may enlarge so the patient should be followed care- fully in the immediate post-treatment period and if they develop any new symptoms (such as reduced visual fields) an urgent MRI should be requested. In the absence of such symptoms patients usually have MRI imaging 3–4 months following radio- therapy and then annually.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">17.17 <span class="h4">Benign nerve sheath tumours of the CNS</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Schwannomas are the most common lesions occurring on the cranial nerves, particu- larly the vestibulocochlear nerve (‘vestibular schwannoma’, also previously errone- ously called acoustic neuroma) or the spinal nerves. There are seen more frequently in patients with neurofibromatosis 2 (NF2) for which vestibular schwannomas are considered pathognomonic if bilateral. Proper neurofibromas can occur on the spinal nerve roots but do not occur on the cranial nerves. These are connected with neuro- fibromatosis 1 (NF1). The presenting symptoms reflect the nerve involved, with, for example, patients with vestibular schwannoma presenting with dizziness and ipsilateral hearing loss.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s128" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">	</p><p style="text-indent: 0pt;text-align: left;"><span><img width="189" height="131" alt="image" src="Image_265.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"><span><img width="193" height="131" alt="image" src="Image_266.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Fig. 17.18 <span class="s52">Vestibular schwannoma (a) MRi before sRs. (b) MRi after sRs.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.17.1 <span class="s29">Imaging features</span></p><p style="padding-top: 2pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">See Figure 17.18a (pre-SRS) and Figure 17.18b (post-SRS).</p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Extra-axial mass centred on internal auditory canal (IAC)</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May be intracanalicular or extend into cerebellopontine angle cistern</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">May expand IAC</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Avid uniform enhancement</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">‘Ice cream cone’ appearance typical</span></p><p class="s23" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">◆ <span class="p">Can extend to fundus and vestibulocochlear labyrinth</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.17.2 <span class="s29">Radiotherapy target definition</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Radiotherapy, delivered either as radiosurgery or a fractionated stereotactic radio- therapy is often used to treat schwannomas not amenable to surgical resection. The target should be defined on a T1-weighted contrast enhanced MRI scan with the GTV encompassing the enhancing lesion. Check the cochlear aperture and basal turn care- fully. No CTV margin is required.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.17.3 <span class="s29">Follow-up imaging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These patients undergo annual MRI scanning for 5–10 years to detect recurrences which might be amenable to surgery. On follow-up imaging following stereotactic radiosurgery, around a third of lesions enlarge on the first post-treatment MRI and then the size stabilizes. Over time, lesions may be slow to reduce in size, but often de- velop central cystic change with corresponding with loss of enhancement.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">17.18 <span class="h4">Orbital lesions</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">A number of tumours or other lesions can occur in the orbits, potentially threatening sight. The most common lesions seen by an oncologist are:</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">17.18.1 <span class="s29">Dysthyroid eye disease/thyroid orbitopathy</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">See Figure 17.19.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: left;">Swelling of the intra-orbital muscles (usually bilateral) associated with thyroid dysfunction. The extra-ocular muscle enlargement typically spares the tendinous</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 53pt;text-indent: 0pt;text-align: left;"><span><img width="297" height="239" alt="image" src="Image_267.gif"/></span></p><p class="s24" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 17.19 <span class="s52">thyroid orbitopathy.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">insertions. Proliferation of orbital fat is also usually seen. This condition is sometimes treated with radiotherapy where the ocular muscles are treated to reduce the inflam- matory infiltrate.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.18.2 <span class="s29">Pseudo-tumour</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These are usually asymmetrical or unilateral diffuse inflammatory change within the orbital tissues, which are often painful. The aetiology is unknown, but this can occa- sionally require radiotherapy if systemic treatments fail.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.18.3 <span class="s29">Orbital lymphoma</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These usually involve unilateral swelling of the orbital tissues, including the adnexa/ lacrimal glands. These lesions are often MALTomas or other types of non-Hodgkin lymphoma (NHL) as part of a systemic disease.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.18.4 <span class="s29">Metastases</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">These occur either to the soft tissues, resulting in proptosis or diplopia, or choroid, producing reduced visual acuity and eventually blindness. These are treated pallia- tively, encompassing the orbit either unilaterally or bilaterally depending on the patient’s general condition and previous treatment.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">17.18.5 <span class="s29">Meningioma</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">This can affect either the optic nerve or an extension of a parasellar lesion. These can be successfully treated with radiotherapy, sometimes with improvement of vision. The classical description of optic nerve meningioma radiologically is of a ‘tram track’ appearance.</p><p class="s73" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">Further reading</p><p style="padding-top: 5pt;padding-left: 24pt;text-indent: -12pt;text-align: left;"><a href="https://www.nice.org.uk/guidance/ng99" style=" color: #231F20; font-family:&quot;Palatino Linotype&quot;, serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8.5pt;" target="_blank">NICE guideline [NG99] Brain tumours (primary and brain metastases in adults </a><a href="https://www.nice.org.uk/guidance/ng99" class="a" target="_blank">https://www. </a><a href="https://www.nice.org.uk/guidance/ng99" target="_blank">nice.org.uk/guidance/ng99</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">1. <b>Niyazi M</b>, <b>Brada M</b>, <b>Chalmers AJ</b>, (2016). ESTRO-ACROP guideline ‘target delineation of glioblastomas’. <i>Radiotherapy &amp; Oncol</i>ogy, <b>118</b>(1): 35–42.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">2. <b>Louis DN</b>, <b>Perry A</b>, <b>Reifenberger G, et al. </b>(2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. <i>Acta Neuropathology</i>, <b>131</b>(6): 803–820.</p><p class="s74" style="padding-top: 1pt;padding-left: 24pt;text-indent: -10pt;text-align: left;">3. <b>Weber DC</b>, <b>Wang Y</b>, <b>Miller R, et al. </b>(2015). Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. <i>Neuro-oncology</i>, <b>17</b>(4): 588–595.</p><p class="s74" style="padding-top: 1pt;padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4. <b>Maclean J</b>, <b>Fersht N</b>, <b>Short S </b>(2014). Controversies in radiotherapy for meningioma.</p><p class="s74" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Clinical Oncology </i>(Royal College of Radiologists), <b>26</b>(1): 51–64.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part22.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part24.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
